Dr Timothy Coogan is the Founder and Principal of South Basin Associates (SBA), an independent consulting company focused on Nonclinical Drug Safety.  Tim has expertise in building nonclinical safety assessment strategies for biologic and small molecule therapeutics in order to guide safe first in human use and continued clinical development through registration.  

Prior to founding SBA, Tim worked for 26 years at Johnson & Johnson (J&J) within their pharmaceutical sector holding various positions with increasing responsibility.  From 2013, he was Vice President and Head of the Biologics Toxicology group in Janssen Biotherapeutics, the former Centocor organization.  In 2017, he became Global Head of Nonclinical Safety with overall responsibility for the nonclinical safety assessment of biologic and small molecule therapeutics in the Janssen R&D portfolio.  During his career, Tim and his team have had responsibility for the development of many biologic and small molecule therapeutics, a number of which ultimately achieved global registration and approval.  Additionally, Tim served as a member of the First-in-Human Early Development Committee evaluating potential therapeutics in the Janssen portfolio for safe administration in human. 

Dr Coogan earned a Ph.D. in Pharmacology from the University of the Sciences (formerly The Philadelphia College of Pharmacy & Science) and is Board Certified in Toxicology (DABT). He was a postdoctoral fellow at NYU Medical Center and came to J&J from the US National Cancer Institute in 1992.  From 2006 to 2017, Tim was an Adjunct Assistant Professor in the School of Pharmacy at Temple University.